Mayne Knocked Back Again On US NuvaRing Rival
Pledges To Address Issues Raised In FDA Complete Response Letter
Executive Summary
Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.
You may also be interested in...
Mayne And Mithra Add Further US NuvaRing Rival
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.
Three Not A Magic Number For Mayne With Another NuvaRing CRL
Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.
Estetrol Approvals Mark 'Turning Point' For Mithra
Recent Canadian, European and US endorsements of Mithra’s estetrol-based Estelle novel oral contraceptive mark a “turning point” for the Belgian firm, which has also seen success with its Myring generic rival to NuvaRing for which it expects to see further launches this year.